298 related articles for article (PubMed ID: 26022710)
41. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Rajkumar SV; Lacy MQ; Kyle RA
Blood Rev; 2007 Sep; 21(5):255-65. PubMed ID: 17367905
[TBL] [Abstract][Full Text] [Related]
42. Should bone marrow examination be routinely performed for the diagnosis of monoclonal gammopathy of undetermined significance?
Elis A; Radnay J; Shapiro H; Itzhaky D; Manor Y; Lishner M
Isr Med Assoc J; 2006 Dec; 8(12):840-2. PubMed ID: 17214099
[TBL] [Abstract][Full Text] [Related]
43. Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20.
Palma BD; Guasco D; Pedrazzoni M; Bolzoni M; Accardi F; Costa F; Sammarelli G; Craviotto L; De Filippo M; Ruffini L; Omedè P; Ria R; Aversa F; Giuliani N
Leukemia; 2016 Feb; 30(2):409-16. PubMed ID: 26419509
[TBL] [Abstract][Full Text] [Related]
44. Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis.
Andersen NF; Kristensen IB; Preiss BS; Christensen JH; Abildgaard N
Eur J Haematol; 2015 Sep; 95(3):211-7. PubMed ID: 25353275
[TBL] [Abstract][Full Text] [Related]
45. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.
Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; López Corral L; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Olavarría E; Quintana N; García JL; Bladé J; Lahuerta JJ; San Miguel JF
N Engl J Med; 2013 Aug; 369(5):438-47. PubMed ID: 23902483
[TBL] [Abstract][Full Text] [Related]
46. Pathogenesis of myeloma.
Anderson KC; Carrasco RD
Annu Rev Pathol; 2011; 6():249-74. PubMed ID: 21261519
[TBL] [Abstract][Full Text] [Related]
47. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients.
Paiva B; Gutiérrez NC; Chen X; Vídriales MB; Montalbán MÁ; Rosiñol L; Oriol A; Martínez-López J; Mateos MV; López-Corral L; Díaz-Rodríguez E; Pérez JJ; Fernández-Redondo E; de Arriba F; Palomera L; Bengoechea E; Terol MJ; de Paz R; Martin A; Hernández J; Orfao A; Lahuerta JJ; Bladé J; Pandiella A; Miguel JF;
Leukemia; 2012 Aug; 26(8):1862-9. PubMed ID: 22333880
[TBL] [Abstract][Full Text] [Related]
48. How I treat smoldering multiple myeloma.
Ghobrial IM; Landgren O
Blood; 2014 Nov; 124(23):3380-8. PubMed ID: 25298034
[TBL] [Abstract][Full Text] [Related]
49. Genomic patterns of progression in smoldering multiple myeloma.
Bolli N; Maura F; Minvielle S; Gloznik D; Szalat R; Fullam A; Martincorena I; Dawson KJ; Samur MK; Zamora J; Tarpey P; Davies H; Fulciniti M; Shammas MA; Tai YT; Magrangeas F; Moreau P; Corradini P; Anderson K; Alexandrov L; Wedge DC; Avet-Loiseau H; Campbell P; Munshi N
Nat Commun; 2018 Aug; 9(1):3363. PubMed ID: 30135448
[TBL] [Abstract][Full Text] [Related]
50. Advances in the management of asymptomatic myeloma.
Mateos MV
Curr Opin Oncol; 2014 Nov; 26(6):670-6. PubMed ID: 25210868
[TBL] [Abstract][Full Text] [Related]
51. MYC protein expression is detected in plasma cell myeloma but not in monoclonal gammopathy of undetermined significance (MGUS).
Xiao R; Cerny J; Devitt K; Dresser K; Nath R; Ramanathan M; Rodig SJ; Chen BJ; Woda BA; Yu H
Am J Surg Pathol; 2014 Jun; 38(6):776-83. PubMed ID: 24705315
[TBL] [Abstract][Full Text] [Related]
52. Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance.
Skrtić A; Korać P; Krišto DR; Ajduković Stojisavljević R; Ivanković D; Dominis M
Hum Pathol; 2010 Dec; 41(12):1702-10. PubMed ID: 20800871
[TBL] [Abstract][Full Text] [Related]
53. Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice.
Cocito F; Mangiacavalli S; Ferretti VV; Cartia CS; Ganzetti M; Benveuti P; Pompa A; Catalano M; Fugazza E; Landini B; Arcaini L; Corso A
Leuk Lymphoma; 2019 Dec; 60(12):2968-2974. PubMed ID: 31169049
[TBL] [Abstract][Full Text] [Related]
54. Smoldering multiple myeloma: taking the narrow over the wide path?
Avet-Loiseau H; Bahlis NJ
Blood; 2024 May; 143(20):2025-2028. PubMed ID: 38427775
[TBL] [Abstract][Full Text] [Related]
55. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies.
Landgren O
Hematology Am Soc Hematol Educ Program; 2013; 2013():478-87. PubMed ID: 24319222
[TBL] [Abstract][Full Text] [Related]
56. Multiple myeloma: diagnosis and treatment.
Nau KC; Lewis WD
Am Fam Physician; 2008 Oct; 78(7):853-9. PubMed ID: 18841734
[TBL] [Abstract][Full Text] [Related]
57. Pseudohyperphosphatemia in a patient with incidentally identified progression of smoldering myeloma.
Francis ER; Chen F; Kidacki M; Miller R; Alkhasoneh M; Talamo G; Straub M; Klinefelter K; Kodali N; Zhu Y
Clin Chim Acta; 2018 Dec; 487():306-308. PubMed ID: 30315756
[TBL] [Abstract][Full Text] [Related]
58. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.
Lakshman A; Rajkumar SV; Buadi FK; Binder M; Gertz MA; Lacy MQ; Dispenzieri A; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
Blood Cancer J; 2018 Jun; 8(6):59. PubMed ID: 29895887
[TBL] [Abstract][Full Text] [Related]
59. Shall we treat smoldering multiple myeloma in the near future?
Landgren O
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):194-204. PubMed ID: 29222256
[TBL] [Abstract][Full Text] [Related]
60. Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression.
Fernández de Larrea C; Isola I; Pereira A; Cibeira MT; Magnano L; Tovar N; Rodríguez-Lobato LG; Calvo X; Aróstegui JI; Díaz T; Lozano E; Rozman M; Yagüe J; Bladé J; Rosiñol L
Leukemia; 2018 Jun; 32(6):1427-1434. PubMed ID: 29463830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
